Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEKiAUTO: Cobimetinib, Atezolizumab, and Hydroxychloroquine in KRAS-mutated Cancers
NCT04214418Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib, hydroxychloroquine, atezolizumab in pancreatic adenocarcinoma (PDAC), colorectal adenocarcinoma, solid tumor, sponsored by Columbia University. Started Feb 2020; status: terminated.
02
Drugs
cobimetinibhydroxychloroquineatezolizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT04214418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214418.